Monoclonal Antibodies, Paxlovid, Molnupiravir: A COVID-19 treatment update from the FDA

Gerald E. Harmon, MD, welcomes experts from the U.S. Food and Drug Administration (FDA) to discuss what prescribers need to know about COVID-19 therapeutic drugs, Paxlovid and Molnupiravir. Alternative treatment options for high-risk outpatients with mild-moderate COVID-19 will also be discussed. Panelists will answer questions submitted by attendees. Recorded February 1, 2022.

Panel:
• John Farley, MD, MPH, director, Office of Infectious Diseases in the Center for Drug Evaluation and Research’s Office of New Drugs, FDA
• Aimee Hodowanec, MD, senior medical officer, Division of Antivirals, Office of Infectious Disease in the Center for Drug Evaluation and Research’s Office of New Drugs, FDA
• Stephanie Troy, MD, senior medical officer, Division of Antivirals, Office of Infectious Disease in the Center for Drug Evaluation and Research’s Office of New Drugs, FDA

Chapters:
0:00 Introduction
2:22 Monoclonal Antibodies: An update from the FDA
5:32 Sotrovimab
6:20 Remdesivir
10:33 Paxlovid and COVID-19: What physicians need to know
25:16 Molnupiravir EUA: What physicians need to know
38:58 Q&A

[americanmedicalassociation]

0:00 Introduction
2:22 Monoclonal Antibodies: An update from the FDA
5:32 Sotrovimab
6:20 Remdesivir
10:33 Paxlovid and COVID-19: What physicians need to know
25:16 Molnupiravir EUA: What physicians need to know
38:58 Q&A